Personalized busulfan dosing before stem cell transplant for blood cancers
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a way to personalize the dose of a chemotherapy drug (busulfan) given before a stem cell transplant, based on how your body processes it. This could make the transplant safer and more effective for people who cannot tolerate the standard high-dose conditioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or younger
- You have acute leukemia, myelodysplastic syndrome, or a myeloproliferative neoplasm
- Your disease is in complete or partial remission, or stable
- You have a suitable stem cell donor (related or unrelated) with a good HLA match
- You are not eligible for standard high-dose conditioning because you are 45 or older, or have a comorbidity score of 3 or higher
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
This trial tests a new way to calculate the dose of the chemotherapy drug busulfan based on a child's body surface area, before a bone marrow transplant. The goal is to make dosing more accurate and possibly improve safety and effectiveness.
This trial tests a special type of stem cell transplant that may help people with certain blood cancers or bone marrow diseases. The transplant uses donor stem cells that are specially selected to reduce the risk of complications. It might be an option for patients who need a transplant to treat their condition.
This trial tests a transplant using stem cells from an unrelated donor who is not a perfect match for your tissue type. It may be an option for people with blood cancers who can't find a fully matched related donor and need a transplant quickly.
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.